UPCNasdaqPharmaceutical PreparationsFiscal year ends September 30

Universe Pharmaceuticals INC

Financials through fiscal 2025, year ended Sep 30, 2025Last filing: 20-F on Jan 29, 2026

$3.76−0.17 (-4.33%)

Close on Oct 19, 2026

Community

Notes and questions about Universe Pharmaceuticals from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Universe Pharmaceuticals's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-600 reverse split on Apr 29, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is UPC.

Revenue growth-22.4% · median 7.3%

Gross margin35.3% · median 64.4%

Operating margin-16.3% · median 11.4%

Net margin-20.6% · median 20.0%

Advertisement
300 × 250